Semaglutide (Sema) Research Peptide

Semaglutide is a modified GLP-1 analogue with 94% sequence homology to human GLP-1.

• A fatty-acid side chain promotes albumin binding, while structural changes reduce degradation by DPP-4.
• Sema and Sema peptide are informal abbreviations; brand names refer to specific finished formulations.

Semaglutide selectively binds to and activates the GLP-1 receptor.

• In pancreatic beta cells it supports glucose-dependent insulin secretion; it also reduces glucagon secretion when glucose is elevated.
• It delays early post-meal gastric emptying, changing the rate at which glucose enters circulation.
• This category covers receptor pharmacology, structure, formulation, storage, analytical identity, and comparisons with related agonists.

Evidence includes laboratory studies, controlled human trials, and post-authorization data for regulated products.

• Findings for Ozempic, Wegovy, or Rybelsus cannot be transferred automatically to compounded or research-labeled material.
• Identity, concentration, excipients, sterility, and regulatory status must be assessed product by product.